Drugs / Autologous Multipotent Mesenchymal Stromal Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03828123 | Jan 2012 → Aug 2017 | amyotrophic lateral sclerosis | Bioinova, s.r.o. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous Multipotent Mesenchymal Stromal Cells | “Intrathecal application of Autologous Multipotent Mesenchymal Stromal Cells 3P suspension” NCT03828123 ↗ |
| Known as | autologous multipotent BM-MSCs | “We have designed a prospective, nonrandomized, open-label clinical trial (phase I/IIa, EudraCT No. 2011-000362-35) to assess the safety and efficacy of autologous multipotent...” PMID 27938483 ↗ Nov 2016 |
| Route | Intrathecal | “cell suspension for intrathecal application will be prepared and introduced intrathecally through lumbar puncture” NCT03828123 ↗ |